Application of the CRISPR/Cas9 system to edit the genomes of human pluripotent stem cells (hPSCs) has the potential to revolutionize hPSC-based disease modeling, drug screening, and transplantation therapy.
Dr. Santos et.al. published protocols to enable groups —even those with limited experience with hPSC culture or the CRISPR/Cas9 system— to successfully perform genome editing using our HilyMax.
HilyMax is a useful tool to support generation of hPSC lines with gene-specific knock-outs, small targeted mutations, or knock-in reporters.
Reference
D. Santos, E. Kiskinis, K. Eggan, and F. Merkle, "Comprehensive protocols for CRISPR/Cas9-based gene editing in human pluripotent stem cells”, CurrProtoc Stem Cell Biol., 2016, 38, 5B.6.1–5B.6.60.
